pCRR | Nano Publications

2018 – ESMO – Phase II/III NBTXR3 in STS

Abstracts, Donnée clinique de NBTXR3, STM

NBTXR3 is a first-in-class Hafnium-Oxide nanoparticle intratumorally (IT) injected. When activated by radiotherapy (RT), it allows for a higher energy deposit than RT alone, yielding an increased tumoral cell death. A phase I study in soft tissue sarcoma (STS) showed that a single NBTXR3 IT injection at 10% of the baseline tumor volume with preoperative RT was technically feasible with manageable toxicity and clinical activity was observed. […]

Continuer la lecture…

2018 – ASTRO 2018 – Phase III NBTXR3 in Soft Tissue Sarcoma

Abstracts, Donnée clinique de NBTXR3, STM

A subset of soft tissue sarcoma (STS) patients achieve significant therapeutic benefit from preoperative radiotherapy (RT). Yet, this treatment paradigm may be associated with limited efficacy and increased toxicity, highlighting the necessity of novel multimodal therapies aimed at local control with few adverse events (AEs). NBTXR3 is a first-in-class Hafnium-Oxide nanoparticle. […]

Continuer la lecture…